In a groundbreaking move, President Donald Trump signed an executive order to expedite the FDA review of psychedelic drugs like ibogaine, psilocybin, and MDMA, aiming to unlock their potential in treating mental health conditions such as PTSD and depression.
Influential figures in the push for this reform include Health Secretary Robert F. Kennedy Jr. and popular podcaster Joe Rogan, who have been vocal advocates for the therapeutic use of psychedelics, particularly for veterans.
The order signifies a dramatic shift in federal drug policy, breaking away from decades of stringent regulations that have classified these substances as high-risk drugs, paving the way for increased research and clinical trials.
With a focus on enhancing mental health care for military veterans suffering from severe conditions, the initiative has sparked a wave of optimism among proponents of psychedelic therapies and advocates for drug reform.
Following the announcement, psychedelic therapy stocks surged, reflecting the growing interest and investment in the burgeoning field of mental health treatment based on these substances.
Trump's executive order marks a pivotal moment in the ongoing conversation about drug policy, suggesting a potential transformation in how society approaches the treatment of mental health issues through innovative therapies.
Top Keywords
Donald Trump/Robert F. Kennedy Jr./Joe Rogan/U.S. Food and Drug Administration/
Break The Web presents the Live Language Model: AI in sync with the world as it moves.
Powered by our breakthrough CT-X data engine, it fuses the capabilities of an LLM with continuously updating world knowledge to unlock real-time product experiences no static model or web search system can match.
71
